X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LB-100 is a PP2A inhibitor which is being evaluated in phase 1/2 clinical trials in combination with Dostarlimab-gxly for the treatment of ovarian clear cell carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2024
Details:
Under the terms of the license agreement, LIXTE will allow LB-100, which is a PP2A inhibitor with Dostarlimab for the treatment of Ovarian Clear Cell Carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders and Stroke
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 26, 2024
Details:
LB-100 is a PP2A inhibitor which is being evaluated in phase 1/2 clinical trials in combination with Dostarlimab-gxly for the treatment of ovarian clear cell carcinoma.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Jemperli (dostarlimab) is a PD-1 inhibitor which is approved along with chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1)-blocking antibody, plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Jemperli (dostarlimab-gxly) is a PD-1 inhibitor which is being developed for the treatment of patients with primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is being evaluated for the treatment of primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
LB-100 is an inhibitor of PP2A, added to dostarlimab significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for Clear-Cell Ovarian Cancer.
Lead Product(s): LB-100,Dostarlimab
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
Jemperli (dostarlimab-gxly) is a PD-1-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is been validated by EU for dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Jemperli (dostarlimab-gxly) is a PD-1-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is been validated by EU for dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Jemperli (dostarlimab-gxly) is a PD-1-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is being investigated for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
Lead Product(s): Paclitaxel,Encequidar,Dostarlimab
Therapeutic Area: Oncology Product Name: Taxol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Athenex
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Jemperli (dostarlimab), is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
Full results from the PERLA phase II trial, including the primary endpoint of ORR and the key secondary endpoint of progression-free survival, with results by programmed death ligand-1 (PD-L1) expression subgroups.
Lead Product(s): Dostarlimab,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AnaptysBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
The publication of phase 3 data, which show that oral Taxol (paclitaxel) plus encequidar significantly improves tumor response in patients with metastatic breast cancer, compared to IV administration.
Lead Product(s): Paclitaxel,Encequidar,Dostarlimab
Therapeutic Area: Oncology Product Name: Taxol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune system effector functions.
Lead Product(s): EOS-448,Dostarlimab
Therapeutic Area: Oncology Product Name: GSK4428859A
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Preclinically, GSK4381562 promotes the activation of both NK cells and T cells, with the potential to elicit a strong anti-tumor response and promote immunological memory.
Lead Product(s): GSK4381562,Dostarlimab
Therapeutic Area: Oncology Product Name: SRF813
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $815.0 million Upfront Cash: $85.0 million
Deal Type: Collaboration March 31, 2022
Details:
Under the agreement with Sagard Healthcare Royalty Partners to monetize a portion of AnaptysBio’s future JEMPERLI royalties and milestones. AnaptysBio intends to utilize the proceeds funding of its wholly-owned preclinical and clinical-stage antibody programs.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sagard Healthcare
Deal Size: Undisclosed Upfront Cash: $250.0 million
Deal Type: Agreement October 25, 2021
Details:
GSK will present new data across the company’s oncology pipeline and portfolio at the upcoming European Society for Medical Oncology (ESMO) Congress 2021, including new data on Jemperli and Zejula, as well as early-stage research in immuno-oncology and oncology cell therapy.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation (SHM) antibody platform and subsequently developed by TESARO, Inc., now a part of GSK, under a collaboration agreement.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Tesaro
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 17, 2021
Details:
Patients received 500 mg of dostarlimab as an intravenous infusion once every three weeks for four doses, followed by 1,000 mg once every six weeks until disease progression or unacceptable toxicity.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2021
Details:
The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).
Lead Product(s): EOS-448,Dostarlimab
Therapeutic Area: Oncology Product Name: EOS-448
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $2,075.0 million Upfront Cash: $625.0 million
Deal Type: Collaboration June 14, 2021
Details:
Jemperli has been granted a conditional marketing authorisation for use in patients with mismatch repair deficient or microsatellite instability-high advanced endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
Dostarlimab is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: GSK4057190
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2021
Details:
Amended deal provides AnaptysBio with increased royalties on dostarlimab sales under the collaboration, a royalty on GSK’s Zejula™ and a one-time cash payment. GSK receives freedom to conduct combination development and commercialization of Zejula™ with 3rd party molecules.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: GSK4057190
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $1,340.0 million Upfront Cash: $1,175.0 million
Deal Type: Agreement October 26, 2020
Details:
Dostarlimab provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient endometrial cancer who progressed on or after a platinum-based regimen.
Lead Product(s): Dostarlimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
